- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Corticosteroid nasal spray of not much benefit for treating post COVID loss of smell: Study
Egypt: The use of corticosteroid nasal spray for the treatment of post COVID-19 loss of smell (anosmia) offers no benefit over the olfactory training, suggests a recent study in the American Journal of Otolaryngology. According to the study, the patients who received mometasone furoate nasal spray as a topical corticosteroid showed no improvement in terms of duration of anosmia, recovery rates, and duration of anosmia.
Since its infectious outbreak in December 2019 in Wuhan in the Hubei Province of China, coronavirus has gripped the entire world causing more than 2 million deaths as of February 2021. Patients with COVID-19 infection mainly present by symptoms of the lower respiratory tract such as cough, fever, chest tightness, and dyspnea, some patients may present with upper respiratory symptoms such as olfactory dysfunction, rhinorrhea, nasal congestion, and sore throat.
Abdelrahman AhmedAbdelalim, Benha Faculty of Medicine, Benha University, Egypt, and colleagues aimed to evaluate the role of the topical corticosteroid, mometasone furoate, nasal spray in the treatment of post COVID-19 anosmia.
For the purpose, the researchers conducted a prospective, randomized, controlled trial among patients with post COVID-19 anosmia. The trial included 100 patients who were randomly assigned to two groups. Group 1 patients (n=50) received mometasone furoate nasal spray in an appropriate dose of 2 puff (100 μg) once daily in each nostril for 3 weeks with olfactory training. Group 2 patients (n=50) were advised to keep on olfactory training only.
Smell assessment was done using (Visual Analog Scale from 0 to 10). The patients were initially evaluated after their recovery from COVID-19 and followed up for 3 weeks. The smell scores were recorded weekly and the duration of smell loss was recorded from the onset of anosmia till the full recovery.
Key findings of the study include:
- In both groups, the smell scores significantly improved by the end of the third week.
- By comparing smell scores between both groups after 1 week, 2 weeks, and 3 weeks of treatment, there were no statistically significant differences between both groups.
- In group 1, (62%) of patients completely recovered their sense of smell after 3 weeks of treatment, compared to (52%) of patients in group 2.
"Till now there is no good evidence suggesting the use of topical corticosteroid in the treatment of post COVID-19 olfactory dysfunction, and according to our results, the olfactory training can be the advice for anosmia in patients recovered from COVID-19 infection," wrote the authors.
The study titled, "Corticosteroid nasal spray for recovery of smell sensation in COVID-19 patients: A randomized controlled trial," is published in the American Journal of Otolaryngology.
DOI: https://www.sciencedirect.com/science/article/pii/S0196070920305780
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751